Silo Pharma Files S-1 Registration
Ticker: SILO · Form: S-1 · Filed: Jul 17, 2024 · CIK: 1514183
| Field | Detail |
|---|---|
| Company | Silo Pharma, Inc. (SILO) |
| Form Type | S-1 |
| Filed Date | Jul 17, 2024 |
| Risk Level | medium |
| Pages | 14 |
| Reading Time | 17 min |
| Key Dollar Amounts | $0.0001, $2.06, $2.725, $6.25, $2.44 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: registration-statement, sec-filing, capital-raise
TL;DR
Silo Pharma just filed an S-1, looks like they're prepping to sell shares.
AI Summary
Silo Pharma, Inc. filed an S-1 registration statement on July 17, 2024, indicating plans to offer securities. The company, formerly known as Uppercut Brands, Inc., is incorporated in Nevada and has its principal executive offices at 677 N. Washington Boulevard, Sarasota, Florida. The filing does not specify the dollar amount or number of shares to be offered at this stage.
Why It Matters
This S-1 filing signals Silo Pharma's intention to raise capital through the public markets, which could fund future growth or operations.
Risk Assessment
Risk Level: medium — S-1 filings indicate a company is seeking to raise capital, which can be a complex process with inherent market risks.
Key Numbers
- 333-280855 — SEC File Number (Identifies this specific registration filing)
- 27-3046338 — IRS Employer Identification Number (Company's tax identification number)
Key Players & Entities
- Silo Pharma, Inc. (company) — Registrant
- July 17, 2024 (date) — Filing Date
- Nevada (jurisdiction) — State of Incorporation
- 677 N. Washington Boulevard, Sarasota, Florida (location) — Principal Executive Offices
- Eric Weisblum (person) — Chief Executive Officer
- Uppercut Brands, Inc. (company) — Former Company Name
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public.
When was this S-1 filing submitted?
The S-1 filing was submitted on July 17, 2024.
What is Silo Pharma, Inc.'s principal executive office address?
Silo Pharma, Inc.'s principal executive offices are located at 677 N. Washington Boulevard, Sarasota, Florida 34236.
Who is the Chief Executive Officer of Silo Pharma, Inc.?
Eric Weisblum is the Chief Executive Officer of Silo Pharma, Inc.
Has Silo Pharma, Inc. operated under different names previously?
Yes, Silo Pharma, Inc. was formerly known as Uppercut Brands, Inc., Point Capital, Inc., and Gold Swap Inc.
Filing Stats: 4,344 words · 17 min read · ~14 pages · Grade level 16.9 · Accepted 2024-07-17 16:45:59
Key Financial Figures
- $0.0001 — ares”) of common stock, par value $0.0001 per share (“Common Stock”),
- $2.06 — Shares”), at an exercise price of $2.06 per share; issued by us to certain accr
- $2.725 — Agent”), at an exercise price of $2.725 per share and (iii) certain common stoc
- $6.25 — Shares”), at an exercise price of $6.25 per share, issued by us to Laidlaw & Co
- $2.44 million — gregate gross proceeds of approximately $2.44 million. However, we cannot predict when and in
- $1.07 — rted sale price of our Common Stock was $1.07. This offering will terminate on the
Filing Documents
- ea0209123-s1_silopharma.htm (S-1) — 293KB
- ea020912301ex5-1_silopharma.htm (EX-5.1) — 19KB
- ea020912301ex23-1_silopharma.htm (EX-23.1) — 3KB
- ea020912301ex-fee_silopharma.htm (EX-FILING FEES) — 12KB
- image_001.jpg (GRAPHIC) — 15KB
- image_002.jpg (GRAPHIC) — 40KB
- image_003.jpg (GRAPHIC) — 14KB
- ex5-1_001.jpg (GRAPHIC) — 3KB
- ex23-1_001.jpg (GRAPHIC) — 8KB
- 0001213900-24-062184.txt ( ) — 439KB
RISK FACTORS
RISK FACTORS 9 JUNE 2024 REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT 10 SEPTEMBER 2022 PUBLIC OFFERING 10 SELLING SHAREHOLDERS 11
USE OF PROCEEDS
USE OF PROCEEDS 14 DIVIDEND POLICY 14
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 15
DESCRIPTION OF SECURITIES THAT THE SELLING SHAREHOLDERS ARE OFFERING
DESCRIPTION OF SECURITIES THAT THE SELLING SHAREHOLDERS ARE OFFERING 16 PLAN OF DISTRIBUTION 16 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY 18 LEGAL MATTERS 18 EXPERTS 18 WHERE YOU CAN FIND MORE INFORMATION 18 INCORPORATION OF DOCUMENTS BY REFERENCE 19 i ABOUT THIS PROSPECTUS This prospectus relates to the offer and resale of up to an aggregate of 1,043,739 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of Silo Pharma, Inc. (the “Company”, “we”, “us” or “our”), consisting of shares of Common Stock issuable upon exercise of: (i) common stock purchase warrants (the “June 2024 Investor Warrants”), to purchase up to 917,432 shares of Common Stock (the “June 2024 Investor Warrant Shares”), at an exercise price of $2.06 per share; issued by us to certain accredited investors on June 6, 2024 in a concurrent private placement and registered direct transaction pursuant to a securities purchase agreement, dated as of June 4, 2024 (the “June 2024 Purchase Agreement”); (ii) common stock purchase warrants (the “June 2024 Placement Agent Warrants”) to purchase 68,807 shares of Common Stock (the “June 2024 Placement Agent Warrant Shares”) issued to H.C. Wainwright & Co., LLC, as exclusive placement agent (the “Placement Agent”), at an exercise price of $2.725 per share and (iii) certain common stock purchase warrants (the “September 2022 Underwriter Warrants,” together with the June 2024 Investor Warrants and the June 2024 Placement Agent Warrants, the “Warrants”), to purchase up to 57,500 shares of Common Stock (the “September 2022 Underwriter Warrant Shares,” together with the June 2024 Investor Warrant Shares and the June 2024 Placement Agent Warrant Shares, the “Warrant Shares”)), at an exe